Cell Therapy IDCT
-
Spine
DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease
Discogenic progenitor cell therapy safely increased disc volume and provided rapid, durable improvements in low back pain, function, quality of…
Read More » -
Spine
DiscGenics to Present at 2022 Cell & Gene Meeting on the Mesa
SALT LAKE CITY, Oct. 5, 2022 /PRNewswire/ — DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Spine
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and…
Read More » -
Biologics
DiscGenics Announces that Cell Therapy IDCT has Passed the Initial Safety Review of its First-in-Human Clinical Trial for Degenerative Disc Disease
SALT LAKE CITY, Jan. 7, 2019 /PRNewswire/ — DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate…
Read More »